Advanced non-small Cell Lung Carcinoma (NSCLC) CheckMate-017 and-057 in the Update: Survival Advantage with Nivolumab vs. Docetaxel is still confirmed

Sankawa Yuri

首页> 外文期刊>Oncology research and treatment. >Advanced non-small Cell Lung Carcinoma (NSCLC) CheckMate-017 and-057 in the Update: Survival Advantage with Nivolumab vs. Docetaxel is still confirmed

【24h】

Advanced non-small Cell Lung Carcinoma (NSCLC) CheckMate-017 and-057 in the Update: Survival Advantage with Nivolumab vs. Docetaxel is still confirmed

机译：更新中的晚期非小细胞肺癌（NSCLC）CheckMate-017和057：Nivolumab与Docetaxel的生存优势仍得到确认

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2016年第12期|共2页
作者
Sankawa Yuri;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Advanced non-small Cell Lung Carcinoma (NSCLC) CheckMate-017 and-057 in the Update: Survival Advantage with Nivolumab vs. Docetaxel is still confirmed [J] . Sankawa Yuri Oncology research and treatment. . 2016,第12期

机译：更新中的晚期非小细胞肺癌（NSCLC）CheckMate-017和057：Nivolumab与Docetaxel的生存优势仍得到确认
2. COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER [J] . Shah S., Matthews S. E., Sarasani S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016,第7期

机译：NIVOLUMAB VS的成本效益。 DOCETAXEL作为晚期非小细胞肺癌的二线治疗
3. Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) [J] . Gettinger S. N., Horn L., Gandhi L., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）在晚期非小细胞肺癌（NSCLC）患者中的长期生存，临床活性和安全性
4. Development of Renewable RNA Reference Standards for Non-Small Cell Lung Carcinoma (NSCLC) Diagnostics [C] . Andrea DAmbroggio, M. Hou, F. Patell-Socha, International Molecular Medicine Tri-Conference. . 2016

机译：非小细胞肺癌（NSCLC）诊断可再生RNA参考标准的开发
5. 4HPR-X radiation mechanisms of interactions in non-small cell lung cancer (NSCLC) cells in vitro. [D] . Nasca, Melita Maria. 2002

机译：4HPR-X辐射在非小细胞肺癌（NSCLC）细胞中相互作用的体外机制。
6. Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer [O] . Hossein Borghaei, Luis Paz-Ares, Leora Horn, -1

机译：Nivolumab vs Docetaxel在晚期非鳞状非小细胞肺癌中的作用
7. PCN123 HEALTH CARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB VERSUS DOCETAXEL: RESULTS FROM THE CHECKMATE 078 (CM078) TRIAL [O] . R. Lawrance, M. DeRosa, F. Taylor, 2019

机译：用Nivolumab治疗的先进非小细胞肺癌（NSCLC）的PCN123患者的医疗资源利用（HCRU）与多元紫杉醇：Checkmate 078（CM078）试验结果

Advanced non-small Cell Lung Carcinoma (NSCLC) CheckMate-017 and-057 in the Update: Survival Advantage with Nivolumab vs. Docetaxel is still confirmed

著录项

相似文献

相关主题

期刊订阅